In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...
In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...
Medical Device Network on MSN
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth
"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported quarter, the company’s adjusted earnings per share (EPS) of 48 ...
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...
DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, ...
While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...
DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback